

Câmara dos Deputados

30 Agosto 2023

**Incorporação de Novas Tecnologias
e Medicamentos**

Seminário de Integração dos Centros e Unidades Especializadas em
Oncologia _ CACONs e UNACONs

FINANCIAMENTO DA SAÚDE NO BRASIL E NO MUNDO



| 2022 | CURRENT EXPENDITURE ON HEALTH Current Prices _ Adapted _ R\$ |
|---------------------------------|--|
| BRAZIL SUS | R\$ 1,941 |
| BRASIL SAÚDE SUPLEMENTAR | R\$ 4,772 |
| AUSTRALIA | R\$ 32,009 |
| REINO UNIDO | R\$ 23,925 |
| CANADA | R\$ 28,556 |
| ESTADOS UNIDOS | R\$ 59,400 |
| FRANÇA | R\$ 22,820 |
| ALEMANHA | R\$ 28,966 |
| DINAMARCA | R\$ 30,007 |

<https://stats.oecd.org>

Adapted by Nelson Teich


HEALTH CARE EXPENDITURE PER CAPITA IN 2020

| World Bank | HC Expenditure per capita (US\$) |
|----------------------------|----------------------------------|
| | |
| High Income | 6,176 |
| Upper Middle Income | 527 |
| Lower Middle Income | 95 |
| Low Income | 34 |
| | |

World Bank accessed 2023 August 15th

<https://data.worldbank.org/indicator/SH.XPD.CHEX.PC.CD>

EQUIDADE



UNIVERSALIDADE

INTEGRALIDADE

HORIZON SCANNING



TRATAMENTO ONCOLÓGICO

- **Drogas para tratamento do Câncer em 2021**
- **Custo médio: US\$ 283,000 R\$ 1.415.000**
- **Aumento de 57% em relação a 2017**

- **Medicamentos orais para cancer em 2021**
- **Custo médio: US\$ 238,000 R\$ 1.190.000**

21 oncology novel active substances (NASs) were initially launched globally in 2022 with 176 total since 2013


Exhibit 25: Global oncology launches of novel active substances (NAS), 2013–2022



Source: IQVIA Institute, Apr 2023.

A total of 115 oncology NASs have launched globally in the past 5 years and 237 over 20 years with large geographic variations

Exhibit 26: Number of oncology novel active substances launched globally and in selected countries




E COMO ANDA A
PESQUISA NO MUNDO?



Oncology trial starts remained at historically high levels in 2022, up 22% from 2018 and primarily focused on rare cancers

Exhibit 1: Clinical trial starts by year, 2012-2022





Source: Citeline Trialrove, IQVIA Institute, Jan 2023.

Estudos avaliando Inibidores PD-1/PD-L1

**China é responsável por 1.287 dos
mais de 3.000 estudos mais
avançados**

PD-1/PD-L1 inhibitor trial starts grew 54% over the last 5 years with 81% of ongoing late-stage trials in single countries


Exhibit 5: PD-1/PD-L1 inhibitor trial starts by phase and ongoing trials by geography



Source: Citeline Trialstrove, IQVIA Institute, Apr 2023.

Drugs from China-headquartered companies have risen to 23% of the oncology pipeline from only 5% a decade ago

Exhibit 3: Number of oncology drugs over time and country share of pipeline Phase I to regulatory submission based on company headquarters location, 2007-2022



Source: IQVIA Pipeline Intelligence, Dec 2022; IQVIA Institute, Apr 2023.

Total non-COVID-19 clinical trial starts decreased by 1% in 2022, while still 8% above the 2019 level

Exhibit 18: Total number of clinical trial starts by phase, 2012-2022




Source: Citeline Trialtrove, Jan 2023.

QUAL O TAMANHO DO
PIPELINE DE DROGAS?



Growth in the clinical pipeline has remained flat since 2020, although 49% above 2017 levels

Exhibit 8: Number of pipeline products Phase I to regulatory submission by therapeutic drug class, 2012–2022



Source: IQVIA Pipeline Intelligence, Dec 2022; IQVIA Institute, Jan 2023.

ALOCAÇÃO EFICIENTE DE RECURSOS

Gastos com Cancer na UE - 1995 a 2018

| Year | 1995 | 2005 | 2010 | 2014 | 2018 |
|--|--------------|------------|------------|--------------|--------------|
| GASTO COM CÂNCER % GASTO TOTAL EM SAÚDE | 5.90% | | | 6.10% | 6.20% |
| GASTO COM MEDICAMENTOS % GASTO TOTAL COM CÂNCER | | 12% | 20% | 23% | 31% |

The Cost of Cancer in Europe 2018. European Journal of Cancer. Thomas Hofmarcher et al. Feb 2020

The Cost and Burden of Cancer in the European Union 1995-2014. European Journal of Cancer. Bengt Jonsson

PERGUNTAS



Em 2022 o custo mediano das drogas lançadas nos Estados Unidos foi de

US\$ 222,000

R\$ 1.110.000

Droga para diabetes (Novembro 2022)

US\$ 194,000

R\$ 970.000

Estados Unidos _ DOENÇAS RARAS

- **Hengenix** **CSL Boehring** **Hemofilia**
 - **US\$ 3,5 Milhões de Dólares****2022 _ novembro**

- **Zolgensma** **Novartis** **Atrofia Muscular Espinhal**
 - **US\$ 2,1 Milhões de dólares****2019**

- **Zynteglo** **Bluebird Bio** **Betatalassemia**
 - **US\$ 2,8 Milhões de dólares****2022**

**Droga para Atrofia Muscular de Duchenne
Medicamento Elevidys
(Sarepta's Gene Therapy)**

Aprovada de forma condicional em junho 2023

Valor: US\$ 3.2 Million dollars